{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:49:33Z","timestamp":1790470173550,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Tenri Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.cancergen.2015.01.003","type":"journal-article","created":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T18:17:31Z","timestamp":1421691451000},"page":"85-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)\/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7"],"prefix":"10.1016","volume":"208","author":[{"given":"Kayo","family":"Takeoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitomo","family":"Maesako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2015.01.003_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cancergen.2013.07.001","article-title":"ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages","volume":"206","author":"Marino-Enriquez","year":"2013","journal-title":"Cancer Genet"},{"key":"10.1016\/j.cancergen.2015.01.003_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3580","article-title":"Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology","volume":"13","author":"Hallberg","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cancergen.2015.01.003_bib3","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-13-3077","article-title":"U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non\u2013small cell lung cancer that is anaplastic lymphoma kinase positive","volume":"20","author":"Malik","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2015.01.003_bib4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cancergen.2015.01.003_bib5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non\u2013small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cancergen.2015.01.003_bib6","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2015.01.003_bib7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2015.01.003_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12185-013-1482-x","article-title":"inv(2)(p23q13)\/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman","volume":"99","author":"Maesako","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cancergen.2015.01.003_bib9","series-title":"ISCN 2013: an international system for human cytogenetic nomenclature","year":"2013"},{"key":"10.1016\/j.cancergen.2015.01.003_bib10","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/leu.2014.166","article-title":"Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)\u2013anaplastic lymphoma kinase (ALK) acute myeloid leukemia","volume":"28","author":"Maesako","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2015.01.003_bib11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07399","article-title":"Oncogenic mutations of ALK kinase in neuroblastoma","volume":"455","author":"Chen","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2015.01.003_bib12","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non\u2013small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2015.01.003_bib13","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cancergen.2015.01.003_bib14","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1747-0285.2011.01239.x","article-title":"Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen","volume":"78","author":"Zhang","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.cancergen.2015.01.003_bib15","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","article-title":"The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers","volume":"70","author":"Sasaki","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2015.01.003_bib16","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/leu.2010.18","article-title":"ALK fusion genes in children with atypical myeloproliferative leukemia","volume":"24","author":"Rottgers","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2015.01.003_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cancergen.2013.12.003","article-title":"RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia","volume":"207","author":"Lim","year":"2014","journal-title":"Cancer Genet"},{"key":"10.1016\/j.cancergen.2015.01.003_bib18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non\u2013small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cancergen.2015.01.003_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776215000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776215000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:39:39Z","timestamp":1761896379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776215000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S2210776215000046"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2015.01.003","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)\/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2015.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}